Experienced in Primary Hyperoxaluria

Xiaoshun S. He

58 Zhongshan 2nd Road, 
Guangzhou, CN 
Experienced in Primary Hyperoxaluria
58 Zhongshan 2nd Road, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Xiaoshun He practices in Guangzhou, China. He is rated as an Experienced expert by MediFind in the treatment of Primary Hyperoxaluria. Their top areas of expertise are Liver Cancer, Hepatic Ischemia, Liver Failure, Liver Transplant, and Kidney Transplant.

Their clinical research consists of co-authoring 231 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Primary Hyperoxaluria.

Locations

58 Zhongshan 2nd Road, Guangzhou, 510080, China
Other Locations
58 Zhongshan 2nd Rd, Guangzhou, 510080, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase I/II, Open Label, Single Arm, Multicenter Study of LioCyx in Subjects With Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation
A Phase I/II, Open Label, Single Arm, Multicenter Study of LioCyx in Subjects With Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation
Enrollment Status: Withdrawn
Publish Date: June 30, 2022
Intervention Type: Biological
Study Drug: LioCyx
Study Phase: Phase 1/Phase 2
A Phase I Study of T Cell Receptor-Redirected T Cell Infusion For Prevention of Hepatocellular Carcinoma Recurrence in Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation
A Phase I Study of T Cell Receptor-Redirected T Cell Infusion For Prevention of Hepatocellular Carcinoma Recurrence in Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma Post Liver Transplantation
Enrollment Status: Completed
Publish Date: June 30, 2022
Intervention Type: Biological
Study Drug: T-cell Receptor
Study Phase: Phase 1
Virtual Imaging-based Early Portal Pressure Gradient (vePPG) After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension
Virtual Imaging-based Early Portal Pressure Gradient (vePPG) After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension
Enrollment Status: Withdrawn
Publish Date: January 08, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Development and Validation of a Radiomics Signature for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1701): a Prospective Multicenter Study
Development and Validation of a Radiomics Signature for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1701): a Prospective Multicenter Study
Enrollment Status: Completed
Publish Date: January 08, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 3 Less Clinical Trials

231 Total Publications

Establishment of liver cancer disease model via normothermic machine perfusion.
Establishment of liver cancer disease model via normothermic machine perfusion.
Journal: The International journal of artificial organs
Published: June 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find He's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile